J Korean Acad Fam Med Search

CLOSE


Korean J Fam Med > Epub ahead of print
Kim, Park, Kim, Kim, Lee, Shin, Baek, and Lee: Association between Liver Function Markers and Menstrual Cycle Irregularity in Korean Female Population

Abstract

Background

The liver plays an important role in gonadal steroid hormone metabolism, which can affect reproductive health, including the menstrual cycle. However, evidence from large population-based studies is limited. Therefore, this study aimed to investigate the association between liver function markers and menstrual cycle irregularities in premenopausal Korean women using nationwide data.

Methods

This study analyzed Data from the Korea National Health and Nutrition Examination Survey 2010–2011. We investigated 3,045 premenopausal women aged 19–59 years. Liver function markers including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, and fatty liver index were analyzed. Multivariable logistic regression analysis was performed to investigate the association between liver function markers and menstrual cycle irregularity while adjusting for confounding factors. Values were presented as odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analysis was also performed.

Results

Baseline characteristic analysis showed that approximately 14.4% of the study population experienced menstrual cycle irregularity. The mean age was 34.5±0.7 years. The highest quartile of serum ALT and AST levels showed significantly higher ORs for menstrual cycle irregularity (adjusted OR, 1.83; 95% CI, 1.26–2.64 and adjusted OR, 1.67; 95% CI, 1.17–2.39, respectively). A similar result was observed in the subgroup analysis.

Conclusion

Liver function markers were positively associated with menstrual cycle irregularities. In clinical settings, women of reproductive age with relatively decreased liver function should be considered for regular follow-up of their reproductive health status.

INTRODUCTION

The menstrual cycle mainly consists of the ovarian and uterine cycles, which are regulated by hormones from the hypothalamic-pituitary-ovarian (HPO) axis [1]. Menstrual cycle disturbances include disturbances of regularity, quantity, frequency, and duration [2]. Approximately 14.2% to 27% of women of reproductive age worldwide experience menstrual cycle irregularities [3-5]. This irregularity is often the result of various benign factors, including weight change, excessive exercise, dietary habits, stress, medication, and smoking, but may also reflect pathologic conditions such as polycystic ovary syndrome (PCOS) and other hormonal imbalances or reproductive disorders [1,6,7]. Although menstrual cycle irregularity is a multifactorial phenomenon, the disturbances are mostly dependent on the HPO axis, which is also partly affected by liver [5,8-11].
The liver and reproductive system are known to have a bidirectional relationship, whereby the liver plays an important role in gonadal steroid hormone metabolism, its transport to tissues, and other metabolic pathways that could affect reproductive health in general. Gonadal steroid hormone signaling influences the pathogenesis of hepatic disorders [8]. Hence, decreased liver function can induce reproductive dysfunction, which can present as menstrual cycle irregularities [12]. Previous studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with PCOS, which often presents with menstrual irregularity, depending on insulin resistance and hyperinsulinemia [12-17]. Furthermore, several studies have shown the normalization of reproductive function, including the menstrual cycle, after liver transplantation in patients with liver diseases [18,19]. It is possible to presume that patients with compromised liver function or NAFLD may have a higher probability of experiencing menstrual cycle irregularity.
Similarly, certain previous studies have investigated the association between the liver and the reproductive system. However, these studies have mainly focused on selected populations, including patients with specific hepatic disorders or post-liver transplantation patients [12,13,17-20]. Consequently, evidence from large population-based studies is currently limited. Liver function markers could be considered convenient tools for monitoring liver function in the general population during regular health checkups.
Therefore, this study aimed to investigate the association between liver function markers and menstrual cycle irregularities in a premenopausal Korean female population using nationwide data.

METHODS

1. Data Source

This nationwide study analyzed data from the 5th Korea National Health and Nutrition Examination Survey (KNHANES) conducted from 2010 to 2011, during which relevant data were collected. The KNHANES is a nationwide survey carried out by the Korean Ministry of Health and Welfare and the Korean Centers for Disease Control and Prevention since 1998. The sample surveys are extracted and conducted annually from January to December and consist of health, nutrition, and examination surveys.
All participants signed an informed consent form prior to the survey, which was reviewed and approved by the Institutional Review Board (IRB) of the Korean Centers for Disease Control and Prevention (IRB approval no., 2010-02CON-21-C and 2011-02CON-06-C).

2. Study Population

Among the total 17,476 participants in the KNHANES 2010–2011, 14,431 were excluded (Figure 1). The exclusion criteria consisted of men (n=7,982), postmenopausal women (n=4,082), pregnancy (n=64), age (under 19 years or over 60 years, n=1,879), history of bilateral salpingo-oophorectomy operation and missing menstrual data (n=12), absence of liver enzymes data (n=94), hepatitis B, C, liver cirrhosis, or hepatic cancer (n=16), and missing covariates (n=302). Finally, the study included 3,045 premenopausal women.

3. Liver Function Markers

Liver function markers include biochemical markers representing the degree of liver damage, including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) [21]. Fatty liver index (FLI) is a noninvasive method for measuring hepatic steatosis and assists in the selection of candidates who are recommended to undergo hepatobiliary ultrasound evaluation [22]. FLI was calculated using the following equation [22]:
FLI=eL / (1+eL)×100
where L=0.953×loge (triglycerides)+0.139×BMI+0.718×loge (GGT)+0.053×waist circumference–15.745
These markers can be routinely evaluated during health checkups and may be elevated in hepatic parenchymal pathologies. In particular, ALT is an enzyme known to be more specific and predominant in the liver than in other organs compared to AST [21].

4. Reproductive Factors

In this study, data on reproductive factors including menstrual cycle regularity, age at menarche, oral contraceptive use, and history of pregnancy were obtained through a self-administered questionnaire. Participants were asked to record their menstrual cycle characteristics. The question about the presence of a regular menstrual cycle was asked, and those who answered “yes” were considered to have regular menstrual cycles, while those who answered “no” were considered to have irregular cycles. Menstrual cycle irregularity was further defined by inquiring about the inter-menstrual duration, specifically whether it was within or exceeded 3 months.

5. Other Variable Selection

Sociodemographic and lifestyle variables including age, alcohol consumption, smoking, physical activity, residential area, and stress perception were considered as covariates. Data on age was collected using the self-administered questionnaire. Those aged 19 years or older were classified as adults. Alcohol consumption within a month of the survey was classified as drinkers and others as non-drinkers. Smoking data obtained from the self-administered questionnaire was classified as current smokers, ex-smokers, and non-smokers. Using the International Physical Activity Questionnaire, physical activity was defined as moderate-intensity exercise for more than 30 minutes a day, 5 days a week, or vigorous-intensity exercise for more than 20 minutes a day, 3 days a week. As for the residential area, subjects who reside in “dong” were defined as urban residents, and those who live in “eup” or “myun” were defined as rural residents. Stress perception was assessed using the self-administered questionnaire.
Anthropometric measurements, including height (m) and weight (kg), were obtained and body mass index (BMI), was calculated by dividing the weight by the square of the height. Waist circumference was measured during normal exhalation. Blood pressure was measured consecutively 3 times in the right arm using a mercury blood pressure meter after a rest of more than 5 minutes. The average of the second and third measurements was used.
Laboratory findings were obtained from a blood test performed after fasting for at least 8 hours. Fasting blood glucose and serum lipid profile (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides) values were included as research data.
Metabolic syndrome was defined by using the criteria of National Cholesterol Education Program Adult Treatment Panel III as fulfilling any three or more of the following conditions: (1) fasting plasma glucose ≥110 mg/dL; (2) blood pressure ≥130/85 mm Hg; (3) triglycerides ≥150 mg/dL; (4) HDL cholesterol <50 mg/dL for women; and (5) waist circumference ≥88 cm for women [23].

6. Statistical Analysis

The data obtained from the KNHANES were analyzed by applying sampling weights to accurately estimate the characteristics of the study population. The baseline characteristics of the study population are represented either as the mean and standard error of the mean or number of participants and weighted percentage. The liver function markers, ALT, AST, and GGT, were expressed as both continuous and categorical variables and grouped into quartiles according to the measured values. In other published studies, an FLI cutoff value of ≥60 was used to rule out hepatic steatosis, and the same cutoff was applied in this study [22]. The comparative baseline characteristics according to the presence or absence of menstrual regularity were analyzed using the t-test for continuous variables and the chi-square test for categorical variables. Analysis of variance was used to evaluate the variance in the mean values of liver function markers according to menstrual cycle regularity and duration. Analysis of covariance adjusted for age, alcohol consumption, smoking, and history of pregnancy was also performed for the mean FLI values.
To evaluate the association between liver function markers and menstrual cycle irregularity, multivariate logistic regression analysis was performed and P-values were calculated. Hierarchical adjustment was performed where model 1 was a non-adjusted value; model 2 was adjusted for social factors such as age, alcohol consumption, and smoking; model 3 was additionally adjusted for factors related to obesity and metabolic diseases including BMI, waist circumference, LDL cholesterol, HDL cholesterol, triglycerides, and metabolic syndrome; and model 4 was additionally adjusted for history of pregnancy. The same analysis was performed separately for the FLI, and the covariates of age, alcohol consumption, smoking status, and history of pregnancy were adjusted. Stratified subgroup analysis was also performed, and P-values for interactions were calculated. Statistical analysis was performed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC, USA), and the statistical significance level was set at P-value <0.05.

RESULTS

1. Baseline Characteristics

Table 1 shows the baseline characteristics of the study population. Among the 3,045 participants, 2,633 (85.6%) had regular menstrual cycles, and 412 (14.4%) experienced menstrual irregularity. There were no differences between the groups in age (P=0.536), alcohol consumption (P=0.207), smoking (P=0.067), physical activity (P=0.892), residential area (P=0.643), or stress perception (P=0.054).
Individuals with menstrual irregularity had significantly higher BMI (P<0.001), waist circumference (P<0.001), LDL cholesterol (P=0.024), and triglycerides (P=0.030) but lower HDL cholesterol (P=0.012). However, those with menstrual irregularity showed a significantly higher prevalence of metabolic syndrome (P=0.011), whereas reproductive factors were associated with a lower history of pregnancy (P=0.002).
Regarding liver function markers, serum ALT and AST levels were significantly higher in the irregular menstrual cycle group (P<0.001) in the continuous variable form. The FLI was also significantly higher in women with irregular menstrual cycles (P<0.001). However, the serum GGT levels did not differ significantly between the groups (P=0.186).

2. Association between Liver Function Markers and Menstrual Cycle Irregularity

The associations between liver function markers and menstrual cycle irregularity are presented in Table 2 as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). In model 1 where no adjustment was made, the highest quartile of serum ALT level and serum AST level had higher ORs for menstrual cycle irregularity (OR, 2.09; 95% CI, 1.47–2.97; OR, 1.74; 95% CI, 1.24–2.43, respectively). In model 4 where multiple covariates were adjusted, the highest quartile of serum ALT level had significantly higher ORs for menstrual cycle irregularity (adjusted OR, 1.83; 95% CI, 1.26–2.64). A similar association between serum AST level and menstrual cycle irregularity (adjusted OR, 1.67; 95% CI, 1.17–2.39) was also observed.
On the contrary, for serum GGT level, the highest quartile of serum GGT level had higher ORs for menstrual irregularity (OR, 1.53; 95% CI, 1.07–2.19) only in the unadjusted model 1. In the adjusted models, the serum GGT levels were not significantly associated with menstrual cycle irregularities.

3. Association between Fatty Liver Index and Menstrual Cycle Irregularity

The associations between FLI and menstrual cycle irregularity are presented in Table 3 as adjusted ORs with 95% CIs. In model 1 where no adjustment was made, the FLI value over the cutoff value of 60 showed a higher OR for menstrual cycle irregularity (OR, 2.12; 95% CI, 1.33–3.39), and in model 3 where all the covariates were adjusted, it also had significantly higher OR for menstrual cycle irregularity (OR, 2.14; 95% CI, 1.31–3.48). The highest quartile of FLI showed significantly higher ORs for menstrual irregularity in both non-adjusted and adjusted models (OR, 1.60; 95% CI, 1.17–2.18; OR, 1.76; 95% CI, 1.23–2.52, respectively).

4. Subgroup Analysis

A similar result was observed in stratified subgroup analyses. Subgroup analyses were performed according to smoking, alcohol consumption, age, LDL cholesterol, triglycerides, history of pregnancy, and physical activity (Table 4). The association between serum ALT levels and menstrual cycle irregularity did not differ among the subgroups of smoking, alcohol consumption, age, LDL cholesterol, triglycerides, history of pregnancy, and physical activity (P for interactions: 0.113, 0.514, 0.081, 0.079, 0.400, 0.154, and 0.538, respectively).

5. Mean Values of Fatty Liver Index according to Menstrual Cycle Characteristics

The mean of FLI was the highest in those with irregular cycle duration exceeding 3 months (29.3±4.3, P<0.001) as shown in Table 5. A similar trend was observed for the adjusted mean where the highest adjusted mean was seen in the group with irregular cycle duration exceeding 3 months (28.6±4.5, P<0.001).

6. Mean Values of Liver Function Markers according to Menstrual Cycle Characteristics

As shown in Figure 2, the mean serum ALT level was the highest in those with irregular cycle duration exceeding 3 months (25.1±3.5, P=0.001). The highest mean was also observed for serum AST level for irregular cycle duration longer than 3 months (23.9±1.9, P<0.001).

DISCUSSION

In this study, a significant positive association was observed between liver function markers and menstrual cycle irregularities in the premenopausal Korean female population. Compared to the lowest quartile, the highest quartile of serum ALT and AST levels showed almost 1.8- and 1.6-fold greater odds of menstrual cycle irregularities, respectively. The elevation of liver enzymes reflects a decrease in hepatic function, which consequently appears to be associated with menstrual cycle disturbances. Additionally, the group with an FLI value of 60 or higher, which could rule out hepatic steatosis, showed 2.1-fold higher odds of menstrual cycle irregularity, elucidating the association between fatty liver and the menstrual cycle.
Previous studies have investigated more specific and smaller-sized samples. However, some of these findings were too limited to be applied to the general population. They analyzed the relationship between the liver and reproductive system, focusing mainly on the underlying hepatic and hormonal interactions in the male reproductive system or on a subset of patients diagnosed with specific diseases, including vascular liver diseases, as well as patients with severely compromised liver function. Several of these studies have discussed the normalization of the menstrual cycle and other reproductive functions after liver transplantation in patients with compromised liver function [18-20,24-26]. In certain studies, disturbances in the HPO axis and consistently low levels of sex steroid hormones throughout the liver disease progression seem to return to normal levels upon liver transplantation, which ameliorates reproductive functions [18,19].
Moreover, previous studies have described possible hypothetical mechanisms underlying menstrual cycle irregularity in women with various hepatic disorders. The liver modulates the reproductive axis by regulating gonadal steroid hormone metabolism and transport to the tissues [8]. The etiology of the hepatic effect on menstrual cycle disturbances has not been fully elucidated. However, previous studies have found it to be related to hypogonadotropic hypogonadism or hyperandrogenism as seen in PCOS [12,14,27]. The former is reported to be due to liver-dependent dysfunction of hypothalamic-pituitary axis and possible primary gonadal failure [18,19,28]. Hyperandrogenism, may result from portosystemic shunting and hyperinsulinemia in patients with liver diseases, which increases androgen production by theca cells [1,12,18,29]. Additionally, the clearance of androstenedione by the hepatic system is downregulated [12]. The changes in sex hormone-binding globulin (SHBG), which functions as the main binding protein for gonadal hormones and their transport, in patients with hepatic disease remain debatable. Hyperinsulinemia may inhibit the hepatic synthesis of SHBG, which may elevate unbound free gonadal hormone levels [1]. In contrast, some studies have shown that SHBG is elevated in relation to hepatic failure and, in turn, induces decreased metabolic clearance of hormones [1,8,12,18,27]. Recently, several studies on the bidirectional relationship between the liver and reproductive system have shown that gonadal steroid hormone signaling may affect the pathogenesis of liver diseases, where long and irregular menstrual cycles are associated with a higher prevalence of NAFLD [8,13]. Our investigation also reported that those with possible hepatic steatosis could be associated with menstrual cycle irregularity, and those with longer duration of menstrual irregularity had the highest mean values of liver function markers, indicating the potential for a bidirectional interaction.
The first limitation of this study is that liver function was not evaluated using more comprehensive and specific tests. Although the liver function markers included in this study are convenient indicators of hepatic function, more advanced evaluations could be conducted to accurately estimate the hepatic functions of the participants, even though routine monitoring may be limited. Second, menstrual cycle data were obtained using a self-administered questionnaire, which could have created recall bias. Third, due to the lack of information on PCOS, which is associated with menstrual irregularities and NAFLD, we were unable to include it as a confounding factor in the analysis. Finally, considering that this was a cross-sectional study, it was difficult to determine the cause-and-effect relationship over time.
However, this study has definite strengths. This is a large-scale analysis conducted using nationwide data with a large sample size and a multistage probability sampling design, meaning that our findings could potentially be applied to the general population. Additionally, this study used data such as liver function markers, which could be obtained from more accessible tests. It also accounted for and adjusted for potential confounding factors, including age, smoking, alcohol consumption, metabolic syndrome, and history of pregnancy.
In conclusion, liver function markers were positively associated with menstrual cycle irregularities. In clinical settings, women of reproductive age with relatively decreased liver function should be recommended a more thorough and regular follow-up of their reproductive health status.

Notes

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

This research was supported by the Korea Medical Institute Research Fund (Q2315271) and funded by the Ministry of Education, Republic of Korea (2020R1I1A1A01067400).

Figure. 1.
Flow diagram of study population selection. BSO, bilateral salpingo-oophorectomy.
kjfm-23-0181f1.jpg
Figure. 2.
Mean values of liver function markers according to menstrual cycle. P-values: serum alanine aminotransferase (ALT) level=0.001, serum aspartate aminotransferase (AST) level <0.001, and serum gamma-glutamyl transferase (GGT) level=0.200.
kjfm-23-0181f2.jpg
Table 1.
Baseline characteristics of the study population
Characteristic Menstrual cycle regularity
P-value
Regular (n=2,633) Irregular (n=412)
Age (y) 34.9±0.2 34.5±0.7 0.536
Alcohol consumption*
 No 409 (14.9) 56 (12.2) 0.207
 Yes 2,224 (85.1) 356 (87.8)
Smoking
 Non-smoker 2,240 (83.0) 333 (78.5) 0.067
 Ex or current smoker 393 (17.0) 79 (21.5)
Physical activity
 No 2,155 (82.2) 330 (82.5) 0.892
 Yes 478 (17.8) 82 (17.5)
Residential area
 Urban (dong) 2,296 (86.1) 353 (85.1) 0.643
 Rural (eup, myun) 337 (13.9) 59 (14.9)
Stress perception
 No 232 (8.2) 28 (5.2) 0.054
 Yes 2,401 (91.8) 384 (94.8)
Body mass index (kg/m²) 22.4±0.1 23.3±0.3 <0.001
 <18.5 239 (9.6) 31 (9.8) <0.001
 ≥18.5 <25.0 1,910 (71.6) 248 (58.4)
 ≥25.0 484 (18.8) 133 (31.8)
Waist circumference (cm) 74.5±0.2 76.7±0.6 <0.001
Systolic blood pressure (mm Hg) 108.3±0.3 109.1±0.7 0.245
Diastolic blood pressure (mm Hg) 71.5±0.3 72.6±0.5 0.050
Fasting blood glucose (mg/dL) 89.9±0.3 91.0±1.2 0.369
Total cholesterol (mg/dL) 178.0±0.7 182.1±2.0 0.054
LDL cholesterol (mg/dL) 105.2±0.6 109.3±1.7 0.024
HDL cholesterol (mg/dL) 54.3±0.3 52.7±0.6 0.012
Triglyceride (mg/dL) 92.8±1.6 100.7±3.6 0.030
Metabolic syndrome
 No 2,511 (94.9) 369 (91.5) 0.011
 Yes 122 (5.1) 43 (8.5)
Age at menarche (y) 13.7±0.04 13.9±0.1 0.089
Oral contraceptives use
 Yes 219 (9.3) 40 (9.8) 0.776
 No 2,414 (90.7) 372 (90.2)
History of pregnancy
 Yes 1,970 (70.1) 287 (60.7) 0.002
 No 663 (29.9) 125 (39.3)
Alanine aminotransferase (IU/L) 14.6±0.3 17.7±0.8 <0.001
 Q1 (<9.3) 568 (23.1) 68 (17.4) <0.001
 Q2 (9.3–11.8) 519 (18.7) 69 (17.2)
 Q3 (11.9–15.9) 842 (31.7) 97 (23.9)
 Q4 (≥16.0) 704 (26.4) 178 (41.5)
Aspartate aminotransferase (IU/L) 17.5±0.2 19.5±0.6 <0.001
 Q1 (<14.1) 636 (24.6) 79 (20.2) <0.001
 Q2 (14.1–15.9) 705 (26.8) 84 (19.0)
 Q3 (16.0–18.7) 527 (19.3) 71 (18.9)
 Q4 (≥18.8) 765 (29.3) 178 (41.8)
Gamma-glutamyl transferase (IU/L) 18.2±0.4 19.4±0.8 0.186
 Q1 (<11.2) 617 (23.8) 76 (20.5) 0.039
 Q2 (11.2–13.7) 530 (19.4) 67 (16.1)
 Q3 (13.8–18.4) 832 (31.5) 123 (30.0)
 Q4 (≥18.5) 654 (25.4) 146 (33.5)
FLI 12.7±0.4 18.4±1.2 <0.001
 <60 2,544 (96.0) 375 (91.9) 0.001
 ≥60 89 (4.0) 37 (8.1)

Values are presented as weighted mean±standard error or number of participants (weighted %).

LDL, low-density lipoprotein; HDL, high-density lipoprotein; FLI, fatty liver index; Q1, the lowest quartile; Q4, the highest quartile.

* Alcohol consumption was defined as alcohol intake ≥1 time(s) per month.

Physical activity was defined using the International Physical Activity Questionnaire. The regular exercise group included subjects who exercised moderately more than 5 times a week for more than 30 minutes a day or vigorously more than 3 times a week for more than 20 minutes a day.

FLI cut-off value was set at ≥60.

Table 2.
Multivariable-adjusted odds ratios of menstrual cycle irregularity according to liver function markers
Odds ratio (95% confidence interval)
Model 1 Model 2 Model 3 Model 4
Serum ALT level
 Q1 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
 Q2 1.23 (0.80–1.87) 1.25 (0.83–1.90) 1.24 (0.81–1.88) 1.24 (0.82–1.88)
 Q3 1.00 (0.68–1.49) 1.03 (0.70–1.54) 0.98 (0.65–1.46) 1.00 (0.68–1.50)
 Q4 2.09 (1.47–2.97) 2.17 (1.54–3.06) 1.82 (1.26–2.63) 1.83 (1.26–2.64)
Serum AST level
 Q1 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
 Q2 0.87 (0.57–1.31) 0.89 (0.59–1.34) 0.89 (0.58–1.35) 0.87 (0.57–1.32)
 Q3 1.20 (0.79–1.81) 1.22 (0.81–1.85) 1.24 (0.82–1.89) 1.20 (0.79–1.83)
 Q4 1.74 (1.24–2.43) 1.83 (1.30–2.57) 1.75 (1.22–2.49) 1.67 (1.17–2.39)
Serum GGT level
 Q1 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
 Q2 0.97 (0.62–1.49) 0.95 (0.62–1.48) 0.96 (0.62–1.49) 0.93 (0.60–1.47)
 Q3 1.11 (0.77–1.61) 1.10 (0.76–1.59) 1.03 (0.71–1.50) 1.00 (0.68–1.46)
 Q4 1.53 (1.07–2.19) 1.51 (1.05–2.17) 1.24 (0.85–1.81) 1.21 (0.83–1.78)

Model 1: non-adjustment; model 2: adjustment for age, alcohol intake, and smoking; model 3: additional adjustment for body mass index, waist circumference, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, and metabolic syndrome; and model 4: additional adjustment for history of pregnancy.

ALT, alanine aminotransferase; Ref, reference; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Q1, the lowest quartile; Q4, the highest quartile.

Table 3.
Multivariable-adjusted odds ratios of menstrual cycle irregularity according to FLI
Odds ratio (95% confidence interval)
Model 1 Model 2 Model 3
FLI
 <60 1 (Ref) 1 (Ref) 1 (Ref)
 ≥60 2.12 (1.33–3.39) 2.17 (1.34–3.49) 2.14 (1.31–3.48)
FLI
 Q1 1 (Ref) 1 (Ref) 1 (Ref)
 Q2 0.62 (0.42–0.92) 0.65 (0.43–0.97) 0.66 (0.44–0.99)
 Q3 0.72 (0.51–1.04) 0.78 (0.53–1.15) 0.80 (0.54–1.17)
 Q4 1.60 (1.17–2.18) 1.76 (1.24–2.50) 1.76 (1.23–2.52)

Model 1: non-adjustment; model 2: adjustment for age; and model 3: additional adjustment for alcohol intake, smoking, and history of pregnancy.

FLI, fatty liver index; Ref, reference; Q1, the lowest quartile; Q4, the highest quartile.

Table 4.
Subgroup analysis of the association between serum ALT level and menstrual cycle irregularity
Subgroup Odds ratio (95% confidence interval)
P for interaction
Q1 Q2 Q3 Q4
Smoking 0.113
 Non-smoker 1 (Ref) 1.50 (0.95–2.37) 1.07 (0.69–1.66) 2.56 (1.70–3.84)
 Ex or current smoker 1 (Ref) 0.58 (0.22–1.49) 0.81 (0.36–1.79) 1.01 (0.46–2.23)
Alcohol consumption 0.514
 No 1 (Ref) 1.66 (0.54–5.09) 0.94 (0.30–2.97) 3.12 (1.14–8.50)
 Yes 1 (Ref) 1.17 (0.73–1.86) 0.99 (0.65–1.51) 1.96 (1.35–2.84)
Age (y) 0.081
 Women <35 1 (Ref) 0.80 (0.46–1.42) 1.00 (0.61–1.65) 1.71 (1.08–2.70)
 Women ≥35 1 (Ref) 3.28 (1.57–6.85) 1.78 (0.89–3.53) 4.62 (2.40–8.88)
LDL cholesterol (mg/dL) 0.079
 <130 1 (Ref) 0.96 (0.61–1.53) 0.90 (0.58–1.38) 1.70 (1.16–2.48)
 ≥130 1 (Ref) 6.06 (2.15–17.07) 2.84 (0.98–8.20) 6.93 (2.75–17.48)
Triglycerides (mg/dL) 0.400
 <150 1 (Ref) 1.13 (0.73–1.76) 0.97 (0.64–1.45) 1.87 (1.30–2.69)
 ≥150 1 (Ref) 3.28 (0.74–14.55) 1.85 (0.36–9.54) 4.15 (1.00–17.23)
History of pregnancy 0.154
 Yes 1 (Ref) 2.01 (1.11–3.62) 1.49 (0.88–2.51) 3.23 (1.99–5.25)
 No 1 (Ref) 0.83 (0.43–1.57) 0.90 (0.48–1.71) 1.73 (1.01–2.97)
Physical activity 0.538
 No 1 (Ref) 1.16 (0.73–1.84) 0.94 (0.60–1.47) 2.00 (1.37–2.92)
 Yes 1 (Ref) 1.80 (0.62–5.22) 1.51 (0.56–4.08) 2.89 (1.09–7.67)

Adjusted for body mass index, waist circumference, age, alcohol intake, smoker, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, metabolic syndrome, and history of pregnancy.

ALT, alanine aminotransferase; Q1, the lowest quartile of serum ALT level; Q4, the highest quartile of serum ALT level; ref, reference.

Table 5.
Mean values of FLI according to menstrual cycle characteristics
Menstrual cycle
P-value
Regular Irregular <90 d Irregular ≥90 d
FLI 12.65±0.42 16.48±1.23 29.33±4.32 <0.001
FLI (adjusted mean) 12.65±0.41 16.61±1.24 28.62±4.48 <0.001

Values are presented as mean±standard error. Adjusted for age, alcohol intake, smoking, and history of pregnancy.

FLI, fatty liver index.

REFERENCES

1. Berek JS, Berek DL, Novak E. Berek & Novak’s gynecology. 16th ed. Philadelphia (PA): Wolters Kluwer; 2020.

2. Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011;29:383-90.
crossref pmid
3. Kwak Y, Kim Y, Baek KA. Prevalence of irregular menstruation according to socioeconomic status: a population-based nationwide cross-sectional study. PLoS One 2019;14:e0214071.
crossref pmid pmc
4. Rafique N, Al-Sheikh MH. Prevalence of menstrual problems and their association with psychological stress in young female students studying health sciences. Saudi Med J 2018;39:67-73.
crossref pmid pmc
5. Saei Ghare Naz M, Rostami Dovom M, Ramezani Tehrani F. The menstrual disturbances in endocrine disorders: a narrative review. Int J Endocrinol Metab 2020;18:e106694.
pmid pmc
6. Bae J, Park S, Kwon JW. Factors associated with menstrual cycle irregularity and menopause. BMC Womens Health 2018;18:36.
crossref pmid pmc pdf
7. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care; Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006;118:2245-50.
crossref pmid pdf
8. Grossmann M, Wierman ME, Angus P, Handelsman DJ. Reproductive endocrinology of nonalcoholic fatty liver disease. Endocr Rev 2019;40:417-46.
crossref pmid pdf
9. Kim DW, Kim DH, Lee SH, Lee CW, Kim H, Park S, et al. The association between serum ferritin and menstrual irregularity in female adults in Korea. Korean J Fam Pract 2018;8:530-4.
crossref
10. Lee SS, Kim DH, Nam GE, Nam HY, Kim YE, Lee SH, et al. Association between metabolic syndrome and menstrual irregularity in middle-aged Korean women. Korean J Fam Med 2016;37:31-6.
crossref pmid pmc
11. Kim YE, Kim DH, Nam GE, Nam HY, Lee SS, Lee SH, et al. Relationship between menstrual irregularity and dyslipidemia in Korean women. Korean J Fam Pract 2015;5:90-6.

12. Stempak-Droissart T, Rousset-Jablonski C, Spritzer PM, Lalhou N, Larger E, Pichard C, et al. Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women. Clin Res Hepatol Gastroenterol 2022;46:101756.
crossref pmid
13. Cho IY, Chang Y, Kang JH, Kim Y, Sung E, Shin H, et al. Long or irregular menstrual cycles and risk of prevalent and incident nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2022;107:e2309-17.
crossref pmid pdf
14. Falzarano C, Lofton T, Osei-Ntansah A, Oliver T, Southward T, Stewart S, et al. Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab 2022;107:258-72.
crossref pmid pdf
15. Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014;20:14172-84.
crossref pmid pmc
16. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009;6:236-47.
crossref pmid pdf
17. Shengir M, Chen T, Guadagno E, Ramanakumar AV, Ghali P, Deschenes M, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open 2021;5:434-45.
crossref pmid pmc pdf
18. Gariani K, Toso C, Philippe J, Orci LA. Effects of liver transplantation on endocrine function: a systematic review. Liver Int 2016;36:1401-11.
crossref pmid pdf
19. Jabiry-Zieniewicz Z, Kaminski P, Bobrowska K, Pietrzak B, Wielgos M, Smoter P, et al. Menstrual function in female liver transplant recipients of reproductive age. Transplant Proc 2009;41:1735-9.
crossref pmid
20. Parolin MB, Rabinovitch I, Urbanetz AA, Scheidemantel C, Cat ML, Coelho JC. Impact of successful liver transplantation on reproductive function and sexuality in women with advanced liver disease. Transplant Proc 2004;36:943-4.
crossref pmid
21. Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J 2016;92:223-34.
crossref pmid pdf
22. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
crossref pmid pmc pdf
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
crossref pmid
24. Cundy TF, O’Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990;31:337-8.
crossref pmid pmc
25. de Koning ND, Haagsma EB. Normalization of menstrual pattern after liver transplantation: consequences for contraception. Digestion 1990;46:239-41.
crossref pmid pdf
26. Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation 1996;62:476-9.
crossref pmid
27. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005;152:501-13.
crossref pmid
28. Cundy TF, Butler J, Pope RM, Saggar-Malik AK, Wheeler MJ, Williams R. Amenorrhoea in women with non-alcoholic chronic liver disease. Gut 1991;32:202-6.
crossref pmid pmc
29. Nakano M, Saeki M, Hagane K. Delayed puberty in girls having biliary atresia. J Pediatr Surg 1990;25:808-11.
crossref pmid


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
INFORMATION FOR AUTHORS AND REVIEWERS
Editorial Office
Room 2003, Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
Tel: +82-2-3210-1537    Tax: +82-2-3210-1538    E-mail: kjfm@kafm.or.kr                

Copyright © 2024 by Korean Academy of Family Medicine.

Developed in M2PI

Close layer
prev next